# The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

> **NCT00159861** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 267 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Sildenafil citrate

## Key facts

- **NCT ID:** NCT00159861
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2021-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159861, "The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00159861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*